Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Bully88on Jun 18, 2021 7:36am
188 Views
Post# 33409981

RE:RE:RE:RE:RE:SZLS website has been updated

RE:RE:RE:RE:RE:SZLS website has been updatedWe will soon get to see Aristotle revenue growth in the next earnings release.

That should be able to give us a base. 

From there we want to see revenue growth in Aristotle, new announcements, and marketing, 

Knowing that Care Oncology is profitable and bringing in strong revenue will also be very reasuring, and should earase the fears that their LOI with them isnt a waste of money.

With Aristotle now being available to the public in America Via their website, they now have access to 328 million people, who are able to connect to a doctor through their phones and computers to have a webchat to have the doctor prescribe the test, Thus beginning their revenue stream. Either they just get the test, dont have cancer and move on, paying us $1500, or they add minimum 2 years of treatment, including more tests, consultations, pills, etc...

The interview posted yesterday is very reasuring that Care Oncology is a smooth sailing company and has both feet through the door, and are very eager to use Aristotle to its fullest potential.

With their Covid revenue continuing to be on pace with their prospectus 1 year and a half in, it is still flowing steady and funding Aristotles intigration into the market.

Very good times ahead for Stage Zero Life Sciences.

Now lets start marketing. 

Cheers, 

Bully


<< Previous
Bullboard Posts
Next >>